Eli Lilly's Retatrutide Is So Hot, The Unlaunched Weight-Loss Drug Is Already Getting Knocked OffInvestors Business Daily • 05/08/26
Heard on the Street: The fastest-growing part of the weight-loss market—and perhaps the most underappreciated driver for both Novo Nordisk and Lilly—is outside the U.S.WSJ • 05/07/26
LLY Stock Pops 16% After Beat-and-Raise Q1: Buy, Hold or Take Profits?Zacks Investment Research • 05/06/26
Lilly commits additional $4.5 billion across Indiana manufacturing sites, opens first dedicated genetic medicine facilityPRNewsWire • 05/06/26
Novo Stock Rises After Earnings. It's Taking the Weight-Loss Drug Fight to Eli Lilly.Barrons • 05/06/26
Lilly's Oral GLP-1 Pill Foundayo Starts Strong in Oral Obesity MarketZacks Investment Research • 05/05/26
Barclays Hikes Eli Lilly Price Target to $1,400: Tirzepatide Momentum Steals the Show24/7 Wall Street • 05/05/26
Lilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 to demonstrate durable disease clearance in ulcerative colitis through four yearsPRNewsWire • 05/05/26
The Most Surprising Thing About Eli Lilly's Impressive Revenue Growth: Just How Much More Potential There IsThe Motley Fool • 05/04/26
Eli Lilly Topples After Weight-Loss Patient Reports A Surprise Side EffectInvestors Business Daily • 05/04/26
'Bubble effect': Weight loss drug fueled growth is putting the pharma sector at risk, report findsCNBC • 05/04/26